Levicept Ltd is a UK‑based biotechnology company developing a novel biological therapy, LEVI‑04 (p75 Sign up to read more
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2025-09-18 | £2.6M |
| Shareholder | Share class | Shares | Holding |
|---|---|---|---|
| MEDICXI SECONDARY I LPCORP | ORDINARY, SERIES A-2, SERIES B-1, SERIES B-2 | 1,282,816 | 42.4% |
| 8888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 88888888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 888888888888888888 | 8888888888 | 888888 | 8888 |
| 8888888888888 | 88888888 |
Companies with the most similar business descriptions.
Persons with significant control are available once you sign up.
Capital raised per employee divides the equity LEVICEPT LTD raised in the last six months by the headcount in its most recent filed accounts. It is a rough read on how capital-intensive the business is: a high figure means the company is raising a lot relative to the number of people it employs, which is typical of hardware, biotech and other research-heavy businesses. Headcount comes from annual accounts and so lags the funding date, often by a year or more.
A share class is a category of shares carrying its own rights over voting, dividends and what happens to the money if the company is sold or wound up. UK companies typically issue Ordinary shares to founders and employees, then create a new Preferred class at each funding round, giving investors priority on proceeds ahead of the Ordinary holders. LEVICEPT LTD has 7 distinct classes on file at Companies House; the rights attached to each are reproduced below as filed.
THE GROWTH SHARES HAVE ATTACHED TO THEM FULL VOTING RIGHTS INCLUDING ONE VOTE PER SHARE ON A POLL. AFTER PAYMENT OF THE SERIES A-1 AND SERIES A-2 PREFERENCE DIVIDEND, ANY REMAINING PROFITS WHICH THE COMPANY MAY DETERMINE TO DISTRIBUTE SHALL BE DISTRIBUTED PRO RATA TO THE HOLDERS OF SERIES A-2 SHARES, SERIES A-1 SHARES, ORDINARY SHARES AND GROWTH SHARES. SEE THE PRESCRIBED PARTICULARS OF THE ORDINARY SHARES FOR THE RIGHTS OF THE GROWTH SHARES TO PARTICIPATE IN A DISTRIBUTION. THE GROWTH SHARES DO NOT CONFER ANY RIGHTS OF REDEMPTION.
AN ORDINARY-SHARE CONVERTED FROM A SERIES A-1 SHARE OR SERIES A-2 SHALL HAVE THE SAME PREFERENCE DIVIDEND RIGHTS AS THE SHARE FROM WHICH IT WAS CONVERTED. AFTER PAYMENT OF THE SERIES A-1 AND SERIES A-2 PREFERENCE DIVIDEND, ANY REMAINING PROFITS WHICH THE COMPANY MAY DETERMINE TO DISTRIBUTE SHALL BE DISTRIBUTED PRO RATA TO THE HOLDERS OF SERIES A-2 SHARES, SERIES A-1 SHARES, ORDINARY SHARES AND GROWTH SHARES. ON A DISTRIBUTION OF ASSETS ON A LIQUIDATION OR A RETURN OF CAPITAL (OTHER THAN A CONVERSION, REDEMPTION OR REPURCHASE OF SHARES) AND ON AN EXIT (AS DEFINED IN THE ARTICLES), THE SURPLUS ASSETS OF THE COMPANY REMAINING AFTER PAYMENT OF ITS LIABILITIES ARE TO BE USED TO PAY THE FOLLOWING AMOUNTS IN THE FOLLOWING ORDER OF PRIORITY (A) FIRST, IN PRIORITY TO ANY OTHER CLASSES OF SHARES, IN PAYING TO HOLDERS OF SERIES A-2 SHARES THE ISSUE PRICE FOR EACH SHARE PLUS ANY ARREARS OR DIVIDEND AND THE SERIES A-2 PREFERENCE DIVIDEND ON THOSE SHARES AND ANY ORDINARY SHARES INTO WHICH THEY HAVE BEEN CONVERTED; (B) SECOND, AFTER THE AMOUNT PAYABLE PURSUANT TO (A) ABOVE HAVE BEEN SETTLED IN FULL BUT IN PRIORITY TO ANY OTHER CLASSES OF SHARES, IN PAYING TO HOLDERS OF SERIES A-1 SHARES THE ISSUE PRICE FOR EACH SUCH SHARE PLUS ANY ARREARS
These are the directors and secretaries who have left LEVICEPT LTD. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.
| 8888 |
| 8888888888888 | 88888888 | 888888 | 8888 |
9 more shareholders on file , sign up free to see.
THE SERIES A-1 SHARES SHALL CARRY THE RIGHT TO ONE VOTE PER SHARE UNLESS, AT THE RELEVANT TIME, THE ISSUED AND OUTSTANDING SERIES A-1 SHARES ARE CONVERTIBLE INTO A GREATER NUMBER OF ORDINARY SHARES OR THE HOLDERS OF ANY OF THE SERIES A-1 SHARES ARE ENTITLED TO ANTI-DILUTION SHARES (AS DEFINED IN THE ARTICLES) WHICH HAVE NOT YET BEEN ISSUED, IN WHICH CASE, EACH HOLDER OF SERIES A-1 SHARES SHALL BE ENTITLED (IN REPECT OF THE SERIES A-1 SHARES HELD) TO EXERCISE SUCH NUMBER OF VOTES AS IS EQUAL TO THE NUMBER OF ORDINARY SHARES OF WHICH HE WOULD BE THE HOLDER ASSUMING (I) HE HAD BEEN ISSUED THE MAXIMUM NUMBER OF ANTI-DILUTION SHARES TO WHICH HE IS OR WAS ENTITLED BY VIRTUE OF HIS HOLDING OF SERIES A-1 SHARES, AND (II) ALL OF THE SERIES A-1 SHARES OF WHICH HE IS (OR WOULD BE, INCLUDING ANY SUCH ANTI-DILUTION SHARES) THE HOLDER WERE CONVERTED INTO ORDINARY SHARES AT THE THEN APPLICABLE CONVERSION RATE.
THE SERIES A-2 SHARES SHALL CARRY THE RIGHT TO ONE VOTE PER SHARE UNLESS, AT THE RELEVANT TIME, THE ISSUED AND OUTSTANDING SERIES A-2 SHARES ARE CONVERTIBLE INTO A GREATER NUMBER OF ORDINARY SHARES OR THE HOLDERS OF ANY OF THE SERIES A-2 SHARES ARE ENTITLED TO ANTI-DILUTION SHARES (AS DEFINED IN THE ARTICLES) WHICH HAVE NOT YET BEEN ISSUED, IN WHICH CASE, EACH HOLDER OF SERIES A-2 SHARES SHALL BE ENTITLED (IN RESPECT OF THE SERIES A-2 SHARES HELD) TO EXERCISE SUCH NUMBER OF VOTES AS IS EQUAL TO THE NUMBER OF ORDINARY SHARES OF WHICH HE WOULD BE THE HOLDER ASSUMING (I) HE HAD BEEN ISSUED THE MAXIMUM NUMBER OF ANTI-DILUTION SHARES TO WHICH HE IS OR WAS ENTITLED BY VIRTUE OF HIS HOLDING OF SERIES A-2 SHARES, AND (II) ALL OF THE SERIES A-2 SHARES OF WHICH HE IS (OR WOULD BE, INCLUDING ANY SUCH ANTI-DILUTION SHARES) THE HOLDER WERE CONVERTED INTO ORDINARY SHARES AT THE THEN APPLICABLE CONVERSION RATE. THE SERIES A-2 SHARES SHALL BE ENTITLED TO A FIXED ANNUAL 8% CASH DIVIDEND ON THE ISSUE PRICE OF EACH SERIES A-2 SHARE TO BE PAID ON THE EARLIEST TO OCCUR OF AN EXIT (AS DEFINED IN THE ARTICLES) OR LIQUIDATION OF THE COMPANY. AFTER PAYMENT OF AN EQUIVALENT PREFERENCE DIVIDEND ON THE SERIES A-1 SHARES, ANY REMAINING PROFITS WHICH THE COMPANY MAY DETERMINE TO DISTRIBUTE SHALL BE DISTRIBUTED PRO RATA TO THE HOLDERS OF SERIES A-2 SHARES, SERIES A-1 SHARES, ORDINARY SHARES AND GROWTH SHARES. SEE THE PRESCRIBED PARTICULARS OF THE ORDINARY SHARES OR THE RIGHTS OF THE SERIES A-2 SHARES TO
THE SERIES B-1 SHARES SHALL CARRY THE RIGHT TO ONE VOTE PER SHARE UNLESS, AT THE RELEVANT TIME, THE ISSUED AND OUTSTANDING SERIES B-1 SHARES ARE CONVERTIBLE INTO A GREATER NUMBER OF ORDINARY SHARES OR THE HOLDERS OF ANY OF THE SERIES B-1 SHARES ARE ENTITLED TO ANTI-DILUTION SHARES (AS DEFINED IN THE ARTICLES) WHICH HAVE NOT YET BEEN ISSUED, IN WHICH CASE, EACH HOLDER OF SERIES B-1 SHARES SHALL BE ENTITLED (IN REPECT OF THE SERIES B-1 SHARES HELD) TO EXERCISE SUCH NUMBER OF VOTES AS IS EQUAL TO THE NUMBER OF ORDINARY SHARES OF WHICH HE WOULD BE THE HOLDER ASSUMING (I) HE HAD BEEN ISSUED THE MAXIMUM NUMBER OF ANTI-DILUTION SHARES TO WHICH HE IS OR WAS ENTITLED BY VIRTUE OF HIS HOLDING OF SERIES B-1 SHARES, AND (II) ALL OF THE SERIES B-1 SHARES OF WHICH HE IS (OR WOULD BE, INCLUDING ANY SUCH ANTI-DILUTION SHARES) THE HOLDER WERE CONVERTED INTO ORDINARY SHARES AT THE THEN APPLICABLE CONVERSION RATE. SUBJECT TO THE PAYMENT OF THE SERIES PREFERENCE DIVIDEND AND THE SERIES A-2 PREFERENCE DIVIDEND THE SERIES B-1 SHARES SHALL BE ENTITLED TO A FIXED ANNUAL 8% CASH DIVIDEND ON THE ISSUE PRICE OF EACH SERIES B-1 SHARE TO BE PAID ON THE EARLIEST TO OCCUR OF AN EXIT (AS DEFINED IN THE ARTICLES) OR LIQUIDATION OF THE COMPANY. ANY REMAINING PROFITS WHICH THE COMPANY MAY DETERMINE TO DISTRIBUTE SHALL BE DISTRIBUTED PRO RATA TO THE HOLDERS OF SERIES B-1, SERIES A-2 SHARES, SERIES A-1 SHARES, ORDINARY SHARES AND GROWTH SHARES. SEE THE PRESCRIBED PARTICULARS OF THE ORDINARY SHARES FOR THE RIGHTS OF THE SERIES A-1 SHARES TO PARTICIPATE IN A DISTRIBUTION. THE SERIES A-1 SHARES DO NOT CONFER ANY RIGHTS OF REDEMPTION.
THE SERIES B-3 SHARES SHALL CARRY THE RIGHT TO ONE VOTE PER SHARE UNLESS, AT THE RELEVANT TIME, THE ISSUED AND OUTSTANDING SERIES B-3 SHARES ARE CONVERTIBLE INTO A GREATER NUMBER OF ORDINARY SHARES OR THE HOLDERS OF ANY OF THE SERIES B-3 SHARES ARE ENTITLED TO ANTI-DILUTION SHARES (AS DEFINED IN THE ARTICLES) WHICH HAVE NOT YET BEEN ISSUED, IN WHICH CASE, EACH HOLDER OF SERIES B-3 SHARES SHALL BE ENTITLED (IN REPECT OF THE SERIES B-3 SHARES HELD) TO EXERCISE SUCH NUMBER OF VOTES AS IS EQUAL TO THE NUMBER OF ORDINARY SHARES OF WHICH HE WOULD BE THE HOLDER ASSUMING (I) HE HAD BEEN ISSUED THE MAXIMUM